-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Chemomab Therapeutics Ltd. quarterly/annual Income Tax Expense (Benefit) history and change rate from 2018 to 2024.
- Chemomab Therapeutics Ltd. Income Tax Expense (Benefit) for the quarter ending 30 Jun 2024 was $0.000, a 100% decline year-over-year.
- Chemomab Therapeutics Ltd. annual Income Tax Expense (Benefit) for 2024 was $0.000.
- Chemomab Therapeutics Ltd. annual Income Tax Expense (Benefit) for 2023 was $0.000.
- Chemomab Therapeutics Ltd. annual Income Tax Expense (Benefit) for 2022 was -$534,000.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)